Targeting striatal cholinergic interneurons in Parkinson's disease: Focus on metabotropic glutamate receptors

A. Pisani, P. Bonsi, D. Centonze, P. Gubellini, G. Bernardi, P. Calabresi

Research output: Contribution to journalArticle

Abstract

In the early sixties, anticholinergic drugs were introduced in the pharmacological treatment of Parkinson's disease (PD). The rationale behind their utilisation in the treatment of the disease was based on the evidence of an imbalance between the dopaminergic inputs and the intrinsic cholinergic innervation within the striatum. Metabotropic glutamate (mGlu) receptors have been shown to play a key role in striatal function both in physiological conditions and in experimental models of diseases affecting this brain area. Indeed, compelling electrophysiological and morphological evidence shows that mGlu receptors are highly expressed at cellular level and exert a profound modulatory role on cholinergic interneurons excitability. This review will provide a brief survey of studies on the localization and function of mGlu receptors in cholinergic interneurons. The potential relevance of these findings in the control of motor function and in the treatment of PD will be discussed.

Original languageEnglish
Pages (from-to)45-56
Number of pages12
JournalNeuropharmacology
Volume45
Issue number1
DOIs
Publication statusPublished - Jul 2003

Fingerprint

Corpus Striatum
Metabotropic Glutamate Receptors
Interneurons
Cholinergic Agents
Parkinson Disease
Cholinergic Antagonists
Brain Diseases
Theoretical Models
Pharmacology
Pharmaceutical Preparations

Keywords

  • Cholinergic interneuron
  • Metabotropic glutamate receptors
  • Parkinson's disease
  • Striatum
  • Tonically active neurons

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Drug Discovery
  • Pharmacology

Cite this

Targeting striatal cholinergic interneurons in Parkinson's disease : Focus on metabotropic glutamate receptors. / Pisani, A.; Bonsi, P.; Centonze, D.; Gubellini, P.; Bernardi, G.; Calabresi, P.

In: Neuropharmacology, Vol. 45, No. 1, 07.2003, p. 45-56.

Research output: Contribution to journalArticle

@article{40d900c9cad64972877b586a06d2a752,
title = "Targeting striatal cholinergic interneurons in Parkinson's disease: Focus on metabotropic glutamate receptors",
abstract = "In the early sixties, anticholinergic drugs were introduced in the pharmacological treatment of Parkinson's disease (PD). The rationale behind their utilisation in the treatment of the disease was based on the evidence of an imbalance between the dopaminergic inputs and the intrinsic cholinergic innervation within the striatum. Metabotropic glutamate (mGlu) receptors have been shown to play a key role in striatal function both in physiological conditions and in experimental models of diseases affecting this brain area. Indeed, compelling electrophysiological and morphological evidence shows that mGlu receptors are highly expressed at cellular level and exert a profound modulatory role on cholinergic interneurons excitability. This review will provide a brief survey of studies on the localization and function of mGlu receptors in cholinergic interneurons. The potential relevance of these findings in the control of motor function and in the treatment of PD will be discussed.",
keywords = "Cholinergic interneuron, Metabotropic glutamate receptors, Parkinson's disease, Striatum, Tonically active neurons",
author = "A. Pisani and P. Bonsi and D. Centonze and P. Gubellini and G. Bernardi and P. Calabresi",
year = "2003",
month = "7",
doi = "10.1016/S0028-3908(03)00137-0",
language = "English",
volume = "45",
pages = "45--56",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Targeting striatal cholinergic interneurons in Parkinson's disease

T2 - Focus on metabotropic glutamate receptors

AU - Pisani, A.

AU - Bonsi, P.

AU - Centonze, D.

AU - Gubellini, P.

AU - Bernardi, G.

AU - Calabresi, P.

PY - 2003/7

Y1 - 2003/7

N2 - In the early sixties, anticholinergic drugs were introduced in the pharmacological treatment of Parkinson's disease (PD). The rationale behind their utilisation in the treatment of the disease was based on the evidence of an imbalance between the dopaminergic inputs and the intrinsic cholinergic innervation within the striatum. Metabotropic glutamate (mGlu) receptors have been shown to play a key role in striatal function both in physiological conditions and in experimental models of diseases affecting this brain area. Indeed, compelling electrophysiological and morphological evidence shows that mGlu receptors are highly expressed at cellular level and exert a profound modulatory role on cholinergic interneurons excitability. This review will provide a brief survey of studies on the localization and function of mGlu receptors in cholinergic interneurons. The potential relevance of these findings in the control of motor function and in the treatment of PD will be discussed.

AB - In the early sixties, anticholinergic drugs were introduced in the pharmacological treatment of Parkinson's disease (PD). The rationale behind their utilisation in the treatment of the disease was based on the evidence of an imbalance between the dopaminergic inputs and the intrinsic cholinergic innervation within the striatum. Metabotropic glutamate (mGlu) receptors have been shown to play a key role in striatal function both in physiological conditions and in experimental models of diseases affecting this brain area. Indeed, compelling electrophysiological and morphological evidence shows that mGlu receptors are highly expressed at cellular level and exert a profound modulatory role on cholinergic interneurons excitability. This review will provide a brief survey of studies on the localization and function of mGlu receptors in cholinergic interneurons. The potential relevance of these findings in the control of motor function and in the treatment of PD will be discussed.

KW - Cholinergic interneuron

KW - Metabotropic glutamate receptors

KW - Parkinson's disease

KW - Striatum

KW - Tonically active neurons

UR - http://www.scopus.com/inward/record.url?scp=0038517748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038517748&partnerID=8YFLogxK

U2 - 10.1016/S0028-3908(03)00137-0

DO - 10.1016/S0028-3908(03)00137-0

M3 - Article

C2 - 12814658

AN - SCOPUS:0038517748

VL - 45

SP - 45

EP - 56

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 1

ER -